ArticleFrontiers in microbiology2026
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While fucoidans show anti-atherosclerotic potential, their impact on this gut-host axis is unclear. This study investigated the effects of Methods: Atherosclerosis was induced in New Zealand rabbits via high-fat diet feeding combined with balloon catheter injury. Animals in the experimental groups ( Results: Treatments significantly reduced atherosclerotic plaque formation. This effect was particularly pronounced when fucoidan was combined with simvastatin, reducing plaque formation from 41.77 ± 16.02% to 5.91 ± 8.03% in the abdominal aorta and from 10.72 ± 3.49% to 2.29 ± 2.30% in the thoracic aorta (Model vs. combination group). The treatment also ameliorated hyperlipidemia, as shown by decreased plasma TC (24.55 ± 0.73 to 17.45 ± 0.58 mmol/L) and TG (7.75 ± 0.46 to 0.83 ± 0.25 mmol/L) in the combination group compared to the Model group. Both intervention groups exhibited enhanced microbial diversity and increased species richness across all taxonomic levels compared to the model group. Moreover, fucoidan and combination treatments significantly upregulated 83 and 128 metabolites and downregulated 125 and 121 metabolites, respectively. KEGG enrichment analysis indicated that these metabolic changes were associated with multiple pathways. Moreover, the combination therapy may mitigate certain side effects associated with simvastatin, although this possibility requires further investigation. Conclusion: The combination of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.